Skip to main content

RxNews®

Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.

Tyenne® (tocilizumab-aazg) – New biosimilar formulation launch

July 2, 2024 - Fresenius Kabi announced the launch of Tyenne (tocilizumab-aazg) subcutaneous formulation, a biosimilar to Roche’s Actemra (tocilizumab).

Download PDF

Rx navigation